Friday, 20 Sep 2019

You are here

What To Do After Teriparatide?

Once the clock runs out on teriparatide (TPTD or Forteo), what is the next best option?

A one-year observational study compared switching from daily TPTD to either oral bisphosphonates (BP) therapy or denosumab (DMAb) in patients with primary osteoporosis. Postmenopausal patients (n=78) with a mean age 76.3 years, had taken TPTD therapy for 20.1 (6-24) months  were allocated to either the BP or DMAb groups based on physician's decision. BMD and serum bone turnover markers were monitored every 6 months.

Groups were well matched at baseline and after 12 months. The increase in BMD was significantly greater in the switch-to-DMAb group compared to the switch-to-BP group: lumbar spine (6.2 vs. 2.6%; P<0.01), total hip (4.2 vs. 1.1%; P<0.05), and femoral neck (3.5 vs. 1.4%; P<0.05). The DMAb group showed a significant decrease in some bone turnover markers (TRACP-5b [-55.8 vs. -32.8%; P<0.01] and ucOC [-85.5 vs. -65.0%; P<0.001], but not PINP (-67.5 vs. -62.1%).

In this open-label observational study, switching daily TPTD to DMAb significantly increased BMD and decreased bone resorption markers compared to switching to oral BP at 12 months, and thus may next best option after daily TPTD treatment.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Need for Pre-operative Hyperglycemia Testing Prior to Total Joint Replacement

JAMA reports on a large Medicare cohort study showing that amongst patients undergoing total joint replacement (TJR), preoperative HbA1c testing was performed in 26% to 43% of patients with diabetes and in only 5% of those without diabetes. Importantly research has shown that an elevated HbA1c level is associated with postoperative complications.

Weight Loss Cuts Hospital Stays for Obese TKA Patients

Morbidly obese patients who lost 20 lbs before total knee arthroplasty (TKA) cut their hospital stays by about 1 day, and were 76% less likely to have an extended hospital stay, research showed. 

High-Dose Vitamin D: No Help for Bone Health

Vitamin D might not be much help for strengthening bones among healthy adults without osteoporosis, Canadian researchers reported, even at doses far higher than recommended daily allowances. In a clinical trial assessing three levels of daily vitamin D supplementation -- 400 IU, 4,000 IU, and 10,000 IU -- radial volumetric bone mineral density was significantly lower among those (ages 55-70) taking higher doses for 3 years, according to Steven Boyd, PhD, of the University of Calgary in Canada, and colleagues.

Osteoporosis Tx: Good for Bones, but Not for Cutting Death Risk

Osteoporosis treatments were not linked with reduced overall mortality, according to a meta-analysis of placebo-controlled trial data.

Looking at data from 38 clinical trials, there was no significant association found between all drug-based osteoporosis treatments and overall mortality rate (risk ratio 0.98, 95% CI 0.91-1.05), reported Steven Cummings, MD, of the San Francisco Coordinating Center, and colleagues.

Bisphosphonate Use Associated with Reduced Mortality

The Journal of Bone and Mineral Research (JBMR) has published a report showing that a reduction in the rate of bone loss by nitrogen bisphosphonates was associated with a 40% lower mortality risk.

Accelerated bone loss has been shown to be an independent predictor of mortality risk, but the relationship between bisphosphonates, bone loss, and mortality is unknown.